0000000000180660

AUTHOR

Francesco Purrello

showing 25 related works from this author

Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency

2015

Backgrounds and aims: Adrenal insufficiency (AI) has been reported in patients with stable cirrhosis. A lack of substrates has been suggested as a possible contributing pathogenic mechanism leading to glucocorticoid deficiency in these subjects. To better explore this hypothesis, we studied lipoproteins in cirrhotics with and without AI. Methods. A total of 81 cirrhotic patients and 30 normal volunteers were enrolled. The severity of liver disease was graded by Child-Pugh score. Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and apolipoprotein AI (Apo-AI) levels were evaluated. HDL subfractions were measured by gradient gel electrop…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaHydrocortisoneCohort StudiesLiver diseasechemistry.chemical_compoundHDL cholesterolInternal medicineHDL cholesterol; adrenal insufficiency; cirrhosismedicineAdrenal insufficiencyHumansTriglyceridesAgedHydrocortisoneApolipoprotein AICirrhosiApolipoprotein A-ITriglyceridebusiness.industrycirrhosisCholesterol HDLCase-control studyGastroenterologyMiddle Agedmedicine.diseaseLipoproteins LDLEndocrinologychemistryCase-Control StudiesMultivariate AnalysisFemalelipids (amino acids peptides and proteins)Lipoproteins HDLbusinessadrenal insufficiencyGlucocorticoidmedicine.drugLipoprotein
researchProduct

Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity

2019

Background & Aims: In patients with non-alcoholic fatty liver disease (NAFLD), liver biopsy is the gold standard to detect non-alcoholic steatohepatitis (NASH) and stage liver fibrosis. We aimed to identify differentially expressed mRNAs and non-coding RNAs in serum samples of biopsy-diagnosed mild and severe NAFLD patients with respect to controls and to each other. Methods: We first performed a whole transcriptome analysis through microarray (n = 12: four Control: CTRL; four mild NAFLD: NAS ≤ 4 F0; four severe NAFLD NAS ≥ 5 F3), followed by validation of selected transcripts through real-time PCRs in an independent internal cohort of 88 subjects (63 NAFLD, 25 CTRL) and in an external …

Liver CirrhosisMaleRNA UntranslatedMicroarrayBiopsyGastroenterologyliquid-biopsySeverity of Illness IndexTranscriptomeCohort Studies0302 clinical medicineFibrosisSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseMedicineSettore MED/12 - Gastroenterologiamedicine.diagnostic_testFatty liverArea under the curveNASHUntranslatedMiddle AgedLiver030220 oncology & carcinogenesisLiver biopsyDisease Progression030211 gastroenterology & hepatologyFemalefibrosiAdultmedicine.medical_specialty03 medical and health sciencesPredictive Value of TestsInternal medicineNAFLDliquid‐biopsyExtracellularHumansHepatologybusiness.industryGene Expression Profilingfibrosismedicine.diseaseRNAsMetabolic Liver DiseaseROC CurveRNASteatohepatitisbusinessBiomarkers
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

What changed in the Italian internal medicine and geriatric wards during the lockdown

2021

A total of 48 internal medicine or geriatric wards among the 93 adhering to the register REPOSI answered an online questionnaire aimed to investigate the characteristics and activities of converted and non-converted wards in the crucial period of the first wave of the epidemic, 22 February-4 May 2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Aged; Humans; Italy; Hospitals; Internal MedicineMEDLINEgeriatricSocio-culturalelaw.inventionlockdownHospitalPatient TransportlawPandemicHospital dischargemedicineInternal MedicineAged Hospitals Humans Internal Medicine ItalyHumansLetter to the EditorInternal medicineAgedLS7_9business.industrygeriatric patientsmedicine.diseaseIntensive care unitHospitalsInternal medicine geriatric patients lockdown covid-19Italycovid-19Medical emergencybusinessHuman
researchProduct

Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation

2013

Background Scores for cardio-embolic and bleeding risk in patients with atrial fibrillation are described in the literature. However, it is not clear how they co-classify elderly patients with multimorbidity, nor whether and how they affect the physician's decision on thromboprophylaxis. Methods Four scores for cardio-embolic and bleeding risks were retrospectively calculated for ≥ 65 year old patients with atrial fibrillation enrolled in the REPOSI registry. The co-classification of patients according to risk categories based on different score combinations was described and the relationship between risk categories tested. The association between the antithrombotic therapy received and t…

RegistrieMaleEmbolismAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged; 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal MedicineRetrospective Studiearitmiableeding risk scoreAtrial Fibrillation80 and overatrial fibrillationRegistriesStrokeAged 80 and overAspirineducation.field_of_studyElderly Atrial fibrillation Prediction guides Bleeding risk Cardioembolic risk ThromboprophylaxisPrediction guidesAtrial fibrillationCardiovascular diseaseStrokecardio-embolic scorePlatelet aggregation inhibitorcardio-embolic scores; bleeding risk scores; elderly; Atrial FibrillationFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtyLogistic Modelcardio-embolic scoresPopulationHemorrhageRisk AssessmentelderlyCARDIOEMBOLIC RISKNOBLEEDING RISKInternal medicinemedicineElderly; Atrial fibrillation; Prediction guides; Bleeding risk; Cardioembolic riskbleeding risk scoresPrediction guideInternal MedicineHumanseducationThromboprophylaxisAgedRetrospective StudiesELDERLYbusiness.industryPlatelet Aggregation InhibitorSettore MED/09 - MEDICINA INTERNAWarfarinAnticoagulantAnticoagulantsRetrospective cohort studyAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal Medicinemedicine.diseaseSurgeryLogistic ModelsThromboprophylaxiWarfarinbusinessPlatelet Aggregation Inhibitors
researchProduct

Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.

2014

Background: Increased serum uric acid has been considered a cardiovascular risk factor but no study has assessed its relation with hospital mortality or length of stay. On the basis of data obtained from a prospective registry, the prevalence of gout/hyperuricemia and its association with these and other clinical parameters was evaluated in an Italian cohort of elderly patients acutely admitted to internal medicine or geriatric wards. Methods: While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the findin…

MaleKidney DiseaseSettore MED/09 - Medicina InternahyperuricemiaComorbiditieschemistry.chemical_compoundCardiovascular Diseasegout elderlyAllopurinol; Comorbidities; Elderly; Gout; Hyperuricemia; Outcomes; Age Factors; Aged; Aged 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbidity; Female; Gout; Hospital Mortality; Hospitalization; Humans; Hyperuricemia; Kidney Diseases; Length of Stay; Male; Treatment Outcome; Uric Acid; Internal Medicine; Medicine (all)80 and overMedicineAge FactorHyperuricemiaHospital MortalityOutcomeAged 80 and overOUTCOMESMedicine (all)Age FactorsHospitalizationcomorbidityTreatment OutcomeCardiovascular DiseasesAllopurinol; Comorbidities; Elderly; Gout; Hyperuricemia; OutcomesCohortFemaleKidney DiseasesComorbiditieAllopurinol; Comorbidities; Elderly; Gout; Hyperuricemia; Outcomes; Age Factors; Aged; Aged 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbidity; Female; Gout; Hospital Mortality; Hospitalization; Humans; Hyperuricemia; Kidney Diseases; Length of Stay; Male; Treatment Outcome; Uric AcidHumanmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesAllopurinolAllopurinol; Comorbidities; Elderly; Gout; Hyperuricemia; Outcomes; Age Factors; Aged; Aged 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbidity; Female; Gout; Hospital Mortality; Hospitalization; Humans; Hyperuricemia; Kidney Diseases; Length of Stay; Male; Treatment Outcome; Uric Acid; Internal MedicineallopurinolNOgoutGout allopurinol hyperuricemia comorbidities outcomes elderlyInternal medicineInternal MedicineHumansRisk factorIntensive care medicineAdverse effectAgedELDERLYgout allopurinol hyperuricemia comorbidities outcomes elderlybusiness.industrynutritional and metabolic diseasesLength of Staymedicine.diseaseComorbidityGoutUric AcidchemistryChronic DiseaseUric acidbusiness
researchProduct

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

2016

Aims: The objective of this study was to evaluate the prevalence of the prescription of QT-prolonging drugs at hospital admission and discharge and the risk factors associated with their use in older people (aged 65 years and older). Methods: Data were obtained from the REPOSI (REgistro POliterapie SIMI [Società Italiana di Medicina Interna]) registry, which enrolled 4035 patients in 2008 (n = 1332), 2010 (n = 1380), and 2012 (n = 1323). Multivariable logistic regression was performed to determine the risk factors independently associated with QT-prolonging drug use. QT-prolonging drugs were classified by the risk of Torsades de Pointes (TdP) (definite, possible, or conditional) acc…

MaleTORSADES-DE-POINTES INTERVAL PROLONGATION PATIENT CIPROFLOXACIN COHORT DEATH MULTIMORBIDITY AMIODARONE MORTALITY AIFA.Amiodarone030204 cardiovascular system & hematologyCIPROFLOXACINLogistic regressionAmiodaroneElectrocardiography0302 clinical medicineRisk FactorsTorsades de PointesAtrial Fibrillation80 and overPrevalencePharmacology (medical)030212 general & internal medicineAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalizationmedia_commonAged 80 and overTorsades de PointeAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Pharmacology (medical); Geriatrics and Gerontology; Medicine (all)Medicine (all)DEATHMiddle AgedPatient DischargeHospitalizationLong QT SyndromeCohortHospitalized Older PeopleFemalemedicine.drugHumanDrugmedicine.medical_specialtymedia_common.quotation_subjectMULTIMORBIDITYTorsades de pointesPATIENT03 medical and health sciencesPharmacotherapyInternal medicineINTERVAL PROLONGATIONmedicineHumansTORSADES-DE-POINTESCOHORTMedical prescriptionAIFAAgedbusiness.industryMORTALITYRisk FactorSettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseQT-Prolonging DrugAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Geriatrics and Gerontology; Pharmacology (medical)Physical therapyGeriatrics and Gerontologybusiness
researchProduct

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

2023

: Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diagnosis of familial hypercholesterolemia (FH). This study aimed at determining the prevalence of LPA risk variants in adult individuals with FH enrolled in the Italian LIPIGEN (Lipid Transport Disorders Italian Genetic Network) study, with (FH/M+) or without (FH/M-) a causative genetic variant. Methods and Results An lp(a) [lipoprotein(a)] genetic score was calculated by summing the number risk-increasing alleles inherited at rs3798220 and rs10455872 variants. Overall, in the 4.6% of 1695 patients with clinically diagnosed FH, the phenotype was not explained by a monogenic or polygenic cause …

cardiovascular risklipoprotein(a).familial hypercholesterolemia
researchProduct

Multimorbidity and polypharmacy in the elderly: Lessons from REPOSI

2014

none 10 no The dramatic demographic changes that are occurring in the third millennium are modifying the mission of generalist professionals such as primary care physicians and internists. Multiple chronic diseases and the related prescription of multiple medications are becoming typical problems and present many challenges. Unfortunately, the available evidence regarding the efficacy of medications has been generated by clinical trials involving patients completely different from those currently admitted to internal medicine: much younger, affected by a single disease and managed in a highly controlled research environment. Because only registries can provide information on drug effectiven…

Adverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged; 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies; Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineMalemedicine.medical_specialtyAgingmedia_common.quotation_subjectDrug prescriptionMEDLINEAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Aged; Aged 80 and over; Female; Humans; Internal Medicine; Italy; Male; Registries; Societies Medical; Comorbidity; Geriatrics; Polypharmacy; Internal Medicine; Emergency MedicineDiseaseComorbidityAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; PolypharmacyelderlyAdverse drug effectsPromotion (rank)MedicalmedicineAdverse drug effect80 and overInternal MedicineHumansRegistriesMedical prescriptionmedia_commonAgedGeriatricsPolypharmacyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Emergency Medicine; Internal MedicineMultimorbidity Polypharmacy Aging Drug prescription Multidimensional evaluation Adverse drug effectsMultidimensional evaluationbusiness.industrySettore MED/09 - MEDICINA INTERNAMultimorbiditymedicine.diseaseComorbidityelderly multimorbidity polypharmacyClinical trialItalyGeriatricsFamily medicinePolypharmacyEmergency MedicineFemaleMedical emergencyAdverse drug effects; Aging; Drug prescription; Multidimensional evaluation; Multimorbidity; Polypharmacy; Internal Medicine; Emergency MedicinebusinessSocietiesmultimorbidity; polypharmacy; aging; drug prescription; multidimensional evaluation; adverse drug effectsMultimorbidity; Polypharmacy; Aging; Drug prescription; Multidimensional evaluation
researchProduct

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

2021

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Dat…

MaleSettore MED/09 - Medicina InternaArterial diseaseCross-sectional studyAdult populationCoronary DiseaseDiseaseGlobal HealthMedical and Health SciencesDoenças Cardio e Cérebro-vascularesAnticholesteremic AgentMonoclonalPrevalenceRegistriesFamilial HypercholesterolemiaHumanizedStroke11 Medical and Health SciencesLS2_9Studies CollaborationAnticholesteremic AgentsGeneral MedicineHeart Disease Risk FactorMiddle AgedFHSC global registry dataEuropeTreatment OutcomeLower prevalenceGuidancelipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Familial hypercholesterolaemiaLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyCombination therapyFHSC global registry heterozygous familial hypercholesterolaemiaCardiovascular risk factorsAntibodies Monoclonal HumanizedInsightsAntibodiesNOHyperlipoproteinemia Type IIClinicianMedicine General & InternalInternal medicineGeneral & Internal MedicineHealth SciencesmedicineHumansEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)Cross-Sectional StudieScience & TechnologyGlobal Perspectivebusiness.industryCholesterol LDLmedicine.diseaseCross-Sectional StudiesHeart Disease Risk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids

2019

Abstract Objectives We aimed to analyze the prevalence and impact of COPD in older patients hospitalized in internal medicine or geriatric wards, and to investigate adherence to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, associated clinical factors, and outcomes. Design Data were obtained from REgistro POliterapie SIMI (REPOSI), a prospective multicenter observational registry that enrolls inpatients aged ≥65 years. Setting and Participants Older hospitalized patients enrolled from 2008 to 2016 with a diagnosis of COPD. Measures We evaluated adherence to the 2018 GOLD guidelines at admission and discharge, by examining the prescription of inhaled bronchodi…

Malemajor clinical eventmajor clinical eventsPulmonary Disease Chronic Obstructive0302 clinical medicineOlder patientsAdrenal Cortex Hormones80 and over030212 general & internal medicineLS4_4adherenceProspective StudiesGeneral NursingNursing (all)2901 Nursing (miscellaneous)Aged 80 and overCOPDHealth PolicyGeneral MedicineCOPD guidelines adherence major clinical events older patientsolder patientsObstructive lung diseaseBronchodilator Agentsguidelines adherenceHospitalizationInhalationCOPD; guidelines adherence; major clinical events; older patients; Administration Inhalation; Adrenal Cortex Hormones; Aged; Aged 80 and over; Bronchodilator Agents; Female; Humans; Male; Prospective Studies; Pulmonary Disease Chronic Obstructive; Guideline Adherence; HospitalizationAdministrationFemaleGuideline AdherenceCOPD guidelinesCOPD; guidelines adherence; major clinical events; older patients; Nursing (all)2901 Nursing (miscellaneous); Health Policy; Geriatrics and GerontologyChronic Obstructivemedicine.medical_specialtySocio-culturalePulmonary Disease03 medical and health sciencesolder patientInternal medicineAdministration InhalationmedicineHumansCOPDMedical prescriptionAgedPolypharmacybusiness.industrySettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseConfidence intervalrespiratory tract diseasesCOPD; guidelines adherence; major clinical events; older patientsObservational studyGeriatrics and Gerontologybusiness030217 neurology & neurosurgery
researchProduct

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study

2017

Abstract Background Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDL-cholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality. Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy (LIPIGEN Study). Methods We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network criteria. We performed a parallel sequencing of the major…

0301 basic medicineApolipoprotein ECandidate geneSettore MED/09 - Medicina InternaDatabases FactualApolipoprotein BDNA Mutational AnalysisFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosityPCSK90302 clinical medicineRisk FactorsReceptorsGeneticsHomozygoteAutosomal dominant traitPathogenic variantsGeneral MedicinePrognosisAPOB; Familial hypercholesterolemia; LDLR; PCSK9; Pathogenic variantsCholesterolPhenotypeItalyAutosomal Recessive HypercholesterolemiaApolipoprotein B-100lipids (amino acids peptides and proteins)Proprotein Convertase 9APOBCardiology and Cardiovascular MedicinePreliminary DataGenetic MarkersFamilial hypercholesterolemiaLDLRPCSK9APOBPathogenic variantsHeterozygoteFamilial hypercholesterolemiaBiologyPathogenic variantLDLHyperlipoproteinemia Type II03 medical and health sciencesDatabasesmedicineInternal MedicineHumansAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Internal Medicine; Cardiology and Cardiovascular MedicineGenetic Predisposition to DiseaseFactualPCSK9Settore MED/13 - ENDOCRINOLOGIAAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Cardiology and Cardiovascular Medicine; Internal Medicinemedicine.diseaseAtherosclerosis030104 developmental biologyLDLRReceptors LDLMutationbiology.proteinAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Apolipoprotein B-100; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Preliminary Data; Prognosis; Proprotein Convertase 9; Receptors LDL; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine
researchProduct

Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity

2019

Background: In patients with NAFLD liver biopsy is the gold standard to detect NASH and stage liver fibrosis. We aimed to identify differentially expressed mRNAs and non-coding RNAs in serum samples of biopsy-diagnosed mild and severe NAFLD patients with respect to controls and to each other. Methods: We first performed a whole transcriptome analysis through microarray (n=12: 4 CTRL; 4 mild NAFLD: NAS≤4 F0; 4 severe NAFLD NAS≥5 F3), followed by validation of selected transcripts through qPCRs in 88 subjects: 63 NAFLD, 25 CTRL. A similar analysis was also performed on HepG2 exposed to Oleate:Palmitate or only Palmitate (cellular model of NAFL/NASH) at intracellular/extracellular levels. Tran…

Oncologymedicine.medical_specialtymedicine.diagnostic_testMicroarrayHepatologybusiness.industryGastroenterologyGold standard (test)Bioinformaticsmedicine.diseaseTranscriptomeFibrosisInternal medicineLiver biopsyCohortMedicineLiquid biopsyStage (cooking)businessCoding (social sciences)
researchProduct

Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register

2019

Background: The RePoSi study has provided data on comorbidities, polypharmacy, and sex dimorphism in hospitalised elderly patients. Methods: We retrospectively analysed data collected from the 2010, 2012, 2014, and 2016 data sets of the RePoSi register. The aim of this study was to explore the sex-differences and to validate the multivariate model in the entire dataset with an expanded follow-up at 1 year. Results: Among 4714 patients, 51% were women and 49% were men. The disease distribution showed that diabetes, coronary artery disease, chronic obstructive pulmonary disease, chronic kidney disease, and malignancy were more frequent in men but that hypertension, anaemia, osteoarthritis, de…

medicine.medical_specialtyMultivariate analysislcsh:MedicineSocio-culturaleDisease030204 cardiovascular system & hematologyelderlyArticleCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineMedicine030212 general & internal medicineDepression (differential diagnoses)Polypharmacybusiness.industrylcsh:RGeneral Medicinemedicine.diseaseComorbidityelderly sex profiles disease distribution in-hospital mortality 3-month mortality 1-year mortalityMood disordersdisease distribution1-year mortality3-month mortalitysex profilesbusiness1-year mortality; 3-month mortality; disease distribution; elderly; in-hospital mortality; sex profilesKidney diseasein-hospital mortality
researchProduct

Atorvastatin but not pravastatin impairs mitochondrial function in human pancreatic islets and rat β-cells. Direct effect of oxidative stress

2017

AbstractStatins are a class of drugs widely prescribed as frontline therapy for lowering plasma LDL-cholesterol in cardiovascular risk prevention. Several clinical reports have recently suggested an increased risk of type 2 diabetes associated with chronic use of these drugs. The pathophysiology of this effect remains to be fully elucidated but impaired β-cell function constitutes a potential mechanism. The aim of this study was to explore the effect of a chronic treatment with lipophilic and hydrophilic statins on β-cell function, using human pancreatic islets and rat insulin-secreting INS-1 cells; we particularly focused on the role of mitochondria and oxidative stress. The present study …

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_classmedicine.medical_treatmentAtorvastatinPancreatic isletslcsh:MedicineType 2 diabetes030204 cardiovascular system & hematologyMitochondrionPharmacologymedicine.disease_causeArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicinelcsh:ScienceMultidisciplinarybusiness.industryPancreatic isletsInsulinlcsh:RStatinmedicine.disease030104 developmental biologyEndocrinologymedicine.anatomical_structurelcsh:Qlipids (amino acids peptides and proteins)Statins; Pancreatic isletsbusinessOxidative stressPravastatinmedicine.drug
researchProduct

Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry

2020

Currently, chronic obstructive pulmonary disease (COPD) represents the fourth cause of death worldwide with significant economic burden. Comorbidities increase in number and severity with age and are identified as important determinants that influence the prognosis. In this observational study, we retrospectively analyzed data collected from the RePoSI register. We aimed to investigate comorbidities and outcomes in a cohort of hospitalized elderly patients with the clinical diagnosis of COPD. Socio-demographic, clinical characteristics and laboratory findings were considered. The association between variables and in-hospital, 3-month and 1-year follow-up were analyzed. Among 4696 in-patient…

Malemedicine.medical_specialtyChronic ObstructiveCirrhosisSocio-culturaleComorbidity030204 cardiovascular system & hematologycomorbiditieselderlyPulmonary Disease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicine80 and overCOPDHumans030212 general & internal medicineLS4_4RegistriesHospital MortalityCOPD comorbidities elderly internal medicine in-hospital mortality.Depression (differential diagnoses)Cause of deathAgedRetrospective Studies1-year mortality; 3-month mortality; COPD; comorbidities; elderly; internal medicine; in-hospital mortalityAged 80 and overCOPDbusiness.industry1-year mortality; 3-month mortality; COPD comorbidities elderly internal medicine in-hospital mortalitymedicine.diseaseIm - Original1-year mortality; 3-month mortality; COPD comorbidities elderly internal medicine in-hospital mortality; Aged; Aged 80 and over; Comorbidity; Female; Humans; Internal Medicine; Male; Pulmonary Disease Chronic Obstructive; Registries; Retrospective Studies; Hospital Mortalityinternal medicineClinical diagnosisCohortEmergency Medicine1-year mortality3-month mortalityCOPD comorbidities elderly internal medicine in-hospital mortality1-year mortality 3-month mortality COPD comorbidities elderly internal medicine in-hospital mortality.Observational studyFemalebusiness1 year mortalityin-hospital mortality
researchProduct

Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD

2021

Background and aim: Coffee intake exerts protective effects against non-alcoholic fatty liver disease (NAFLD), although without fully cleared mechanisms. In this study we aimed to assess whether coffee consumption may influence the expression of long non-coding RNAs (lncRNAs) in the liver. Methods: C57BL/6J mice were fed a 12-week standard diet (SD), high-fat diet (HFD) or HFD plus decaffeinated coffee solution (HFD + coffee). Expression of specific lncRNAs involved in NAFLD was analyzed by real-time PCR. For the most differentially expressed lncRNAs, the analysis was also extended to their mRNA targets. Results: Decaffeinated coffee intake reduced body weight gain, prevented NAFLD, lowered…

lncRNA.Liver CirrhosisMalemedicine.medical_specialtyGm16551; H19; NAFLD; coffee; lncRNA; Animals; Coffee; Disease Models Animal; Fatty Liver; Gene Expression; Liver; Liver Cirrhosis; Male; Mice; Mice Inbred C57BL; Non-alcoholic Fatty Liver Disease; RNA Long NoncodingCoenzyme ACircadian clockcoffeeGene ExpressionBiologyInbred C57BLArticlechemistry.chemical_compoundMicelncRNADownregulation and upregulationFibrosisSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDmedicineAnimalsTX341-641Messenger RNANutrition and DieteticsH19Nutrition. Foods and food supplyAnimalGm16551Fatty liverNAFLD; coffee; lncRNA; Gm16551; H19nutritional and metabolic diseasesmedicine.diseaseMice Inbred C57BLFatty LiverDisease Models AnimalEndocrinologychemistryLiverLipogenesisDisease ModelsRNARNA Long NoncodingLong NoncodingSteatosisFood Science
researchProduct

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid…

2022

Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis depends on serum lipoprotein functions, including the HDL capacity to promote cell cholesterol efflux (CEC) and the serum capacity to promote cell cholesterol loading (CLC). The aim of this observational study was to investigate the effect of PCSK9 inhibitors (PCSK9-i) treatment on HDL-CEC and serum CLC in patients with familial hypercholesterolemia (FH). 31 genetically confirmed FH patients were recruited. Blood was collected and serum is…

cardiovascular riskSettore MED/09 - Medicina Internafamilial hypercholesterolemiaPCSK9 inhibitors cardiovascular risk cholesterol efflux capacity cholesterol loading capacity familial hypercholesterolemiaPCSK9 inhibitorsSettore BIO/14 - Farmacologiacholesterol loading capacityBiochemistry Genetics and Molecular Biology (miscellaneous)Molecular BiologyBiochemistrycholesterol efflux capacityPCSK9 inhibitors; cardiovascular risk; cholesterol efflux capacity; cholesterol loading capacity; familial hypercholesterolemiaFrontiers in molecular biosciences
researchProduct

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

2016

Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths. Methods: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed. Results: Among 2535 patients, 558 (22.0 %) were discharged with a diagnos…

Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Cardiology and Cardiovascular MedicineMaleRegistrieTime Factorsantithrombotic therapy; atrial fibrillation; elderly; guidelines; outcomesAtrial fibrillation (AF)Practice PatternsKaplan-Meier Estimate030204 cardiovascular system & hematologyGuidelineoutcomesCoronary artery disease0302 clinical medicineElderlyRisk FactorsAtrial FibrillationAntithrombotic80 and overAge Factor030212 general & internal medicineRegistriesguidelinesAntithrombotic therapy Atrial fibrillation Elderly Guidelines OutcomesPractice Patterns Physicians'OutcomeAged 80 and overFibrinolytic AgentAge FactorsAtrial fibrillationGeneral MedicineTreatment OutcomeItalyAtrial fibrillation (AF) thromboembolism antithrombotic prophylaxisPractice Guidelines as TopicCardiologyFemaleGuideline AdherenceCardiology and Cardiovascular MedicineHumanAntithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Age Factors; Aged; Aged 80 and over; Atrial Fibrillation; Chi-Square Distribution; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Practice Patterns Physicians'; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Practice Guidelines as Topic; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyLogistic ModelTime FactorSocio-culturaleLower riskRisk Assessment03 medical and health sciencesFibrinolytic AgentsInternal medicineThromboembolismmedicineHumansProportional Hazards ModelsAgedAntithrombotic therapyPhysicians'Chi-Square Distributionbusiness.industryProportional hazards modelRisk FactorSettore MED/09 - MEDICINA INTERNAGuidelinethromboembolismmedicine.diseaseAtrial fibrillationLogistic ModelsProportional Hazards Modelantithrombotic prophylaxisbusinessChi-squared distributionFibrinolytic agent
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register

2018

As a consequence of population aging, we have witnessed in internal medicine hospital wards a progressive shift from a population of in-patients relatively young and mainly affected by a single ailment to one of ever older and more and more complex patients with multiple chronic diseases, followed as out-patients by many different specialists with poor integration and inevitably treated with multiple medications. Polypharmacy (defined as the chronic intake of five or more drugs) is associated with increased risks of drug-drug interactions and related adverse effects, prescription and intake errors, poor compliance, re-hospitalization and mortality. With this background, the Italian Society …

Malemedicine.medical_specialtyPopulation ageingDeprescribing; Inappropriate prescription; Medication reconciliation; Multimorbidity; PolypharmacyPopulationSocio-culturale030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineDeprescribingRisk Factors80 and overDeprescribing; Inappropriate prescription; Medication reconciliation; Multimorbidity; Polypharmacy; Internal Medicine; Emergency MedicineInternal MedicinemedicineDeprescribing Inappropriate prescription Medication reconciliation Multimorbidity PolypharmacyHumansMultimorbidityRegistries030212 general & internal medicineMedical prescriptionAdverse effecteducationAgedAged 80 and overPolypharmacyGeriatricseducation.field_of_studybusiness.industryMultimorbidityPatient DischargeHospitalizationDeprescribing; Inappropriate prescription; Medication reconciliation; Multimorbidity; Polypharmacy; Aged; Aged 80 and over; Female; Geriatrics; Hospitalization; Humans; Italy; Male; Multimorbidity; Patient Discharge; Registries; Risk Factors; PolypharmacyItalyGeriatricsFamily medicinePolypharmacyEmergency MedicineMedication reconciliationFemaleDeprescribingbusinessDeprescribing; Inappropriate prescription; Medication reconciliation; Multimorbidity; Polypharmacy;Inappropriate prescriptionInternal and Emergency Medicine
researchProduct

Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients.

2019

Depression is often under-recognized in older patients, even if antidepressants (AD) are commonly prescribed, with a prevalence of use that increase with ageing [ 1 ]. Nevertheless, even if a diagnosis of depression is established, inappropriate treatment can occur [ 2 ]. Beers criteria are the most widely screening tools used to detect inappropriate prescription of drugs in people aged 65 years or more [ 3 ]. Since 2010, attempts to adapt the Beers' criteria have been made in Europe [ 4 , 5 ]. Tricyclic drugs are the ADs to be always avoided in the elderly, owing to their anticholinergic side effects, such as cognitive impairment, delirium, urinary retention and falls [ 3 ]. Selective sero…

Malemedicine.medical_specialtySocio-culturaleInappropriate Prescribing-Potentially inappropriate medication olderPractice Patternsdepression hospitalized patients drugselderlydrugsantidepressivi anzianoPolypharmacy | Inappropriate Prescribing | Medications PIMsantidepressant agent escitalopram paroxetineInternal MedicinemedicineHospital dischargeolderEscitalopramHumansLS4_4Medical prescriptionPractice Patterns Physicians'Depression (differential diagnoses)AgedPolypharmacySertralinePhysicians'antidepressantbusiness.industryTrazodonehospitalized patientsAntidepressive AgentsHospitalizationAcute Disease; Aged; Antidepressive Agents; Female; Humans; Inappropriate Prescribing; Italy; Male; Practice Patterns Physicians'; Hospitalizationantidepressants; elderlyItalyantidepressantsEmergency medicinedepressionAcute DiseasePolypharmacy Inappropriate Prescribing Medications PIMDeliriumFemalePotentially inappropriate medicationmedicine.symptombusinessmedicine.drugEuropean journal of internal medicine
researchProduct

Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)

2017

Background and aims: Primary dyslipidemias are a heterogeneous group of disorders characterized by abnormal levels of circulating lipoproteins. Among them, familial hypercholesterolemia is the most common lipid disorder that predisposes for premature cardiovascular disease. We set up an Italian nationwide network aimed at facilitating the clinical and genetic diagnosis of genetic dyslipidemias named LIPIGEN (LIpid TransPort Disorders Italian GEnetic Network). Methods: Observational, multicenter, retrospective and prospective study involving about 40 Italian clinical centers. Genetic testing of the appropriate candidate genes at one of six molecular diagnostic laboratories serving as nationw…

0301 basic medicineCandidate geneGenetic testingSettore MED/09 - Medicina InternaDatabases FactualDNA Mutational AnalysisDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematology0302 clinical medicineDyslipidemias; Genetic testing; National network; Internal Medicine; Cardiology and Cardiovascular MedicineRisk FactorsProspective StudiesProgram DevelopmentProspective cohort studymedicine.diagnostic_testGeneral MedicinePrognosisCholesterolPhenotypeItalyCardiology and Cardiovascular MedicineGenetic Markersmedicine.medical_specialtyNational networkDyslipidemias; Genetic testing; National networkMEDLINEHyperlipoproteinemia Type II03 medical and health sciencesDatabasesInternal medicinemedicineInternal MedicineHumansGenetic Predisposition to DiseaseFactualGenetic testingRetrospective StudiesDyslipidemiasbusiness.industrySettore MED/13 - ENDOCRINOLOGIARetrospective cohort studymedicine.diseaseAtherosclerosisDyslipidemias; Genetic testing; National network; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Prognosis; Program Development; Prospective Studies; Retrospective Studies; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine030104 developmental biologyEndocrinologyDyslipidemiaGenetic markerMutationbusiness
researchProduct

Heart failure and chronic kidney disease in a registry of internal medicine wards

2014

Background: The aim of the present study was to evaluate the association between heart failure (HF) and chronic kidney disease (CKD) in tertiary care centers using the clinical records of patients enrolled in internal medicine departments.Patients and methods: We used the clinical records of 1380 elderly patients to identify patients with a history of HF and CKD using admission ICD codes and glomerular filtration rate (GFR) formulas. Magnitude and strength of such associations were investigated by univariable and multivariable analysis.Results: Of the 1380 patients enrolled, 27.9% had HF (age 80 ± 7, BMI 27 ± 6 kg/m2) and 17.4% CKD (age 81 ± 7, BMI 26.8 ± 6 kg/m2). Both groups were signific…

medicine.medical_specialtyChronic kidney disease; Elderly; Heart failure; REPOSI; Gerontology; Geriatrics and GerontologyHeart failure; Elderly; Chronic kidney disease; REPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Gerontology; Geriatrics and GerontologyChronic kidney disease; Elderly; Heart failure; REPOSIRenal functionHeart failure; chronic kidney disease; elderly; registry; REPOSIHeart failureregistryTertiary careSleep Apnea SyndromeElderlySleep Apnea SyndromesInternal medicineChronic kidney diseaseEpidemiologymedicineHumansNoninvasive Ventilationbusiness.industryREPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Geriatrics and Gerontology; Gerontologymedicine.diseaseHeart failureHeart failure Elderly Chronic kidney disease REPOSIIcd codesGeriatrics and GerontologybusinessClinical recordBody mass indexGerontologyKidney diseaseHuman
researchProduct

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Ita…

2021

Nonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes, and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the last years, mounting evidence added insights about epidemiology, natural history, diagnosis and lifestyle-based or drug treatment of NAFLD. In this rapidly evolving scenario, members of the Associazione Italiana per lo Studio del Fegato (AISF), the Società Italiana di Diabetologia (SID) and the Società Italiana dell'Obesità (SIO) reviewed current knowledge on NAFLD. The quality of the published evidence is graded, and practical recommendations are made follow…

MaleAdultEndocrinology Diabetes and MetabolismSettore MED/12 - GASTROENTEROLOGIAMedicine (miscellaneous)Settore MED/09GuidelineGuidelinesGuidelines NAFLD NASHNon-alcoholic Fatty Liver DiseaseMedicalNAFLDHumansObesitySocieties MedicalPatient Care TeamNutrition and DieteticsGuidelines; NAFLD; NASH; Adult; Delivery of Health Care; Humans; Obesity; Non-alcoholic Fatty Liver Disease; Sudden Infant DeathHepatologyGastroenterologyNASHDisease ManagementGuidelines; NAFLD; NASH; Adult; Delivery of Health Care; Female; Humans; Italy; Male; Patient Care Team; Societies Medical; Disease Management; Non-alcoholic Fatty Liver DiseasePsychiatry and Mental healthClinical PsychologyItalyGuidelines; NAFLD; NASHFemaleCardiology and Cardiovascular MedicineSocietiesDelivery of Health CareSudden Infant DeathHumanEating and weight disorders : EWD
researchProduct